These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37458596)

  • 1. Implication of
    Matar M; Prince G; Hamati I; Baalbaky M; Fares J; Aoude M; Matar C; Kourie HR
    Pharmacogenomics; 2023 Jun; 24(9):509-522. PubMed ID: 37458596
    [No Abstract]   [Full Text] [Related]  

  • 2. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
    Nickerson ML; Dancik GM; Im KM; Edwards MG; Turan S; Brown J; Ruiz-Rodriguez C; Owens C; Costello JC; Guo G; Tsang SX; Li Y; Zhou Q; Cai Z; Moore LE; Lucia MS; Dean M; Theodorescu D
    Clin Cancer Res; 2014 Sep; 20(18):4935-48. PubMed ID: 25225064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of KDM6A mutation in bladder cancer immune escape.
    Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z
    BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines.
    Özden-Yılmaz G; Savas B; Bursalı A; Eray A; Arıbaş A; Senturk S; Karaca E; Karakülah G; Erkek-Ozhan S
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980177
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kobatake K; Ikeda KI; Nakata Y; Yamasaki N; Ueda T; Kanai A; Sentani K; Sera Y; Hayashi T; Koizumi M; Miyakawa Y; Inaba T; Sotomaru Y; Kaminuma O; Ichinohe T; Honda ZI; Yasui W; Horie S; Black PC; Matsubara A; Honda H
    Clin Cancer Res; 2020 Apr; 26(8):2065-2079. PubMed ID: 32047002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
    Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
    Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical delivery of
    Kong N; Zhang R; Wu G; Sui X; Wang J; Kim NY; Blake S; De D; Xie T; Cao Y; Tao W
    Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35131941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
    Tran N; Broun A; Ge K
    Mol Cell Biol; 2020 Sep; 40(20):. PubMed ID: 32817139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer.
    Qiu H; Makarov V; Bolzenius JK; Halstead A; Parker Y; Wang A; Iyer GV; Wise H; Kim D; Thayaparan V; Lindner DJ; Haber GP; Ting AH; Ren B; Chan TA; Arora V; Solit DB; Lee BH
    Cancer Res; 2023 Mar; 83(6):814-829. PubMed ID: 36638328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
    Liu L; Cui J; Zhao Y; Liu X; Chen L; Xia Y; Wang Y; Chen S; Sun S; Shi B; Zou Y
    Mol Cancer; 2021 May; 20(1):77. PubMed ID: 34006303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
    Barrows D; Feng L; Carroll TS; Allis CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25732-25741. PubMed ID: 32989154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
    Hurst CD; Alder O; Platt FM; Droop A; Stead LF; Burns JE; Burghel GJ; Jain S; Klimczak LJ; Lindsay H; Roulson JA; Taylor CF; Thygesen H; Cameron AJ; Ridley AJ; Mott HR; Gordenin DA; Knowles MA
    Cancer Cell; 2017 Nov; 32(5):701-715.e7. PubMed ID: 29136510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X chromosome protects against bladder cancer in females via a
    Kaneko S; Li X
    Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
    Schulz WA; Lang A; Koch J; Greife A
    Int J Cancer; 2019 Aug; 145(3):614-620. PubMed ID: 30628063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KDM6A Depletion in Breast Epithelial Cells Leads to Reduced Sensitivity to Anticancer Agents and Increased TGFβ Activity.
    Xiao JF; Kua LF; Ding LW; Sun QY; Myint KN; Chia XR; Venkatachalam N; Loh X; Duex JE; Neang V; Zhou S; Li Y; Yang H; Koeffler HP; Theodorescu D
    Mol Cancer Res; 2022 Apr; 20(4):637-649. PubMed ID: 35022315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer.
    Hong Z; Li H; Li L; Wang W; Xu T
    Cancer Biomark; 2017; 18(2):125-131. PubMed ID: 27983522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysine demethylases KDM6A and UTY: The X and Y of histone demethylation.
    Gažová I; Lengeling A; Summers KM
    Mol Genet Metab; 2019 May; 127(1):31-44. PubMed ID: 31097364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.
    Zhang C; Shen L; Zhu Y; Xu R; Deng Z; Liu X; Ding Y; Wang C; Shi Y; Bei L; Wei D; Thorne RF; Zhang XD; Yu L; Chen S
    Theranostics; 2021; 11(6):2691-2705. PubMed ID: 33456567
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
    Lee SW; Park DY; Kim MY; Kang C
    Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.